UBS Group AG Has $8.68 Million Stake in Avalo Therapeutics, Inc. $AVTX

UBS Group AG lifted its stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 956.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 477,816 shares of the company’s stock after acquiring an additional 432,608 shares during the period. UBS Group AG’s holdings in Avalo Therapeutics were worth $8,677,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in AVTX. Geode Capital Management LLC raised its stake in shares of Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after acquiring an additional 2,648 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of Avalo Therapeutics by 10.6% in the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock valued at $4,965,000 after acquiring an additional 95,000 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Avalo Therapeutics by 7,066.8% in the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after acquiring an additional 400,898 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics in the 2nd quarter valued at approximately $56,000. Finally, Aberdeen Group plc bought a new position in shares of Avalo Therapeutics in the 3rd quarter valued at approximately $925,000. 87.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Guggenheim assumed coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective on the stock. Citizens Jmp cut their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Wednesday, April 8th. Finally, HC Wainwright cut their price objective on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Thursday. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $48.13.

Avalo Therapeutics Stock Performance

Shares of Avalo Therapeutics stock opened at $17.74 on Monday. The company’s fifty day simple moving average is $15.83 and its 200-day simple moving average is $16.45. The company has a market cap of $520.31 million, a price-to-earnings ratio of -3.25 and a beta of 0.78. Avalo Therapeutics, Inc. has a 1 year low of $3.43 and a 1 year high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.02. As a group, research analysts forecast that Avalo Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Insider Transactions at Avalo Therapeutics

In other news, insider Mittie Doyle sold 3,970 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $18.01, for a total value of $71,499.70. Following the sale, the insider owned 3,622 shares in the company, valued at approximately $65,232.22. This trade represents a 52.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,457 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total transaction of $111,886.11. Following the completion of the sale, the chief financial officer owned 423 shares in the company, valued at approximately $5,596.29. The trade was a 95.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 138,078 shares of company stock worth $2,501,346. Insiders own 4.46% of the company’s stock.

Avalo Therapeutics News Roundup

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Mizuho raised its price target on Avalo Therapeutics to $45 from $39 and maintained an outperform rating, signaling continued optimism about the company’s longer-term potential. Avalo Therapeutics (NASDAQ:AVTX) Given New $45.00 Price Target at Mizuho
• Positive Sentiment: HC Wainwright reiterated a buy rating and set a $35 target, while Citizens JMP kept a market outperform stance with a $55 target, suggesting analysts still see substantial upside despite trimming estimates. Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $55.00 at Citizens Jmp Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $35.00 at HC Wainwright
• Neutral Sentiment: Several firms adjusted their valuation targets in both directions, including Wedbush cutting its target to $34 and Citizens JMP lowering its target to $55, which may be contributing to volatility but does not signal a bearish consensus. Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $34.00 by Analysts at Wedbush
• Negative Sentiment: The company also urged investors to review Form 10-Q risk factors amid ongoing uncertainty, which is likely pressuring shares by reminding the market of regulatory and execution risks. Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.